...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Announces Corporate Update Conference Call & Webcast on June 18, 2020 and US$5 Million Equity Investment

1) Good that the Chinese partner steps up

2) Wondering why there are modifications to their licensing deal

3) No warrants, but still a down round, from 2$ to 1.5$ USD

4) Will the update look like RVXs?

Share
New Message
Please login to post a reply